Individual Study / CAMICCov

A Cell-based Assay to Measure Immune Competence in SARS-CoV-2 Infection and Vaccination

A Cell-based Assay to Measure Immune Competence in SARS-CoV-2 Infection and Vaccination

Networks -
Datasets -
Variables -
Start Year
2021

Members

Download
Investigators Contacts
  • Dr. Sacha De Serres
    Laval University - University Health Centre of Quebec
  • Dr. Sacha De Serres
    Laval University - University Health Centre of Quebec

Design

Study design
Other : This study has two aims: the first aim was carried out with a case-control design and the second aim was using the ongoing TCAD project which is a cohort study.
Follow Up
Participants with severe or mild COVID-19 infection are followed-up 4 to 12 weeks after their enrollment. Participants who are immunosuppressed patients are followed-up 4 to 12 weeks after enrollment and 21 days after the second dose of COVID vaccine.
Supplementary Information
For each case, a control will be selected among the household, matched 1:1 based on age (5 years of difference).

Recruitment

Recruitment Target
  • Individuals

Number of Participants

Number of Participants
210
Number of Participants with Biological Samples
210
Supplementary Information
Severe COVID: 75 participants
Mild COVID: 75 participants
Immunosuppressed: 60 participants

Access

Availability of data and biosamples

Possible Access to Data
Possible Access to Biosamples
Other

Timeline

Populations

Selection Criteria
Newborns
Twins
Countries
  • Canada
Territory
Ethnic Origin
Health Status
  • Participants were included if they were already diagnosed with COVID-19 infection since the beginning of the pandemic and have positive Epstein-Barr virus (EBV) serologic status.
Other Criteria
Participants are included if they have a history of hospitalization to care for COVID-19 infection.

Recruitment

Sources of recruitment
  • Specific population
Specific Population
  • Clinic patients
Supplementary Information
Patients will be identified based on the COVID registry established locally. They will be contacted and recruited by the nephrology research nurses and students.

Number of Participants

Number of Participants
75
Number of Participants with Biological Samples
75
Data Collection Events
# Name Description Start End
0 CAMICCov - Severe COVID - Enrollment Blood samples was collected. Information about demographic, medical history, medication, COVID-19 (length of hospitalization, residual symptoms, etc.) was collected. 2019-12 2022-01
1 CAMICCov - Severe COVID - Follow-up Blood samples was collected. 2020-01 2022-03
Selection Criteria
Newborns
Twins
Countries
  • Canada
Territory
Ethnic Origin
Health Status
  • Participants were included if they were already diagnosed with COVID-19 infection since the beginning of the pandemic and have positive Epstein-Barr virus (EBV) serologic status.
Other Criteria
Participants are included if they did not have a history of hospitalization to care for COVID-19 infection and are member of the household of a case.

Recruitment

Sources of recruitment
  • Specific population
Specific Population
  • Clinic patients
Supplementary Information
Patients will be identified based on the COVID registry established locally. They will be contacted and recruited by the nephrology research nurses and students.

Number of Participants

Number of Participants
75
Number of Participants with Biological Samples
75
Data Collection Events
# Name Description Start End
0 CAMICCov - Mild COVID - Enrollment Blood samples was collected. Information about demographic, medical history, medication, COVID-19 (length of hospitalization, residual symptoms, etc.) was collected. 2019-12 2022-01
1 CAMICCov - Mild COVID - Follow-up Blood samples was collected. 2020-01 2022-03
Selection Criteria
Newborns
Twins
Countries
  • Canada
Territory
Ethnic Origin
Health Status
  • Participants are included if they are stable kidney recipients.
Other Criteria
Supplementary Information about selection criteria

Recruitment

Sources of recruitment
  • Participants from existing studies
Supplementary Information
Participants enrolled in this study are among the TCAD cohort enrolled in the Quebec city area.
Participants from Existing Studies
  • TCAD

Number of Participants

Number of Participants
60
Number of Participants with Biological Samples
60
Data Collection Events
# Name Description Start End
0 CAMICCov - Immunosuppressed - Enrollment Blood samples was collected. Information about demographic, medical history, medication, COVID-19 (length of hospitalization, residual symptoms, etc.) and vaccination (company, dates of the ... 2021-10 2022-01
1 CAMICCov - Immunosuppressed - Follow-up 1 Blood samples was collected. 2021-11 2022-03
2 CAMICCov - Immunosuppressed - Follow-up 2 Blood samples was collected. 2021-12 2022-04

Classifications

Socio-demographic and economic characteristics
Lifestyle and behaviours
Birth, pregnancy and reproductive health history
Perception of health, quality of life, development and functional limitations
Diseases
Symptoms and signs
Medication and supplements
Non-pharmacological interventions
Health and community care services utilization
Death
Physical measures and assessments
Laboratory measures
Cognition, personality and psychological measures and assessments
Life events, life plans, beliefs and values
Preschool, school and work life
Social environment and relationships
Physical environment
Administrative information

Socio-demographic and economic characteristics

Age/birthdate
Sex/gender
Ethnicity, race and religion
Other socio-demographic and economic characteristics

Lifestyle and behaviours

Tobacco
Nutrition
Physical activity

Perception of health, quality of life, development and functional limitations

Functional limitations

Diseases

Certain infectious and parasitic diseases (A00-B99)
Neoplasms (C00-D48)
Endocrine, nutritional and metabolic diseases (E00-E90)
Diseases of the circulatory system (I00-I99)
Diseases of the respiratory system (J00-J99)
Diseases of the genitourinary system (N00-N99)
Injury, poisoning and certain other consequences of external causes (S00-T98)
Diseases without precise specification or falling into multiple categories

Symptoms and signs

Symptoms related to multiple categories

Medication and supplements

Medication and supplement intake
Posology and protocol of administration

Non-pharmacological interventions

Surgical interventions
Laboratory diagnosis interventions
Other and unspecified non-pharmacological interventions

Health and community care services utilization

Hospitalizations

Death

Vital status
Cause of death

Physical measures and assessments

Anthropometry
Circulation and respiration

Laboratory measures

Hematology
Biochemistry
Virology
Immunology
Histology
Genomics

Administrative information

Identifiers
Date and time-related information
Physical and cognitive measure and biosample-related information
Data and sample collection center-related information
Other administrative information